Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/08/2005US20050272770 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
12/08/2005US20050272769 8-hydroxy-5-[(R)-1-hydroxy-2-(6-phenethylamino-hexylamino)ethyl]-1H-quinolin-2-one; pulmonary disease: asthma or chronic obstructive pulmonary disease, pre-term labor, a neurological disorder, a cardiac disorder, or inflammation; long duration of action
12/08/2005US20050272768 Process for preparation of amorphous form of a drug
12/08/2005US20050272767 Method for treating myolytic disease and method for screening antimyolytic agent
12/08/2005US20050272766 1-Glyoxylamide indolizines for treating lung and ovarian cancer
12/08/2005US20050272765 Dipeptidyl peptidase inhibitors
12/08/2005US20050272764 Imidazopyridine compound
12/08/2005US20050272763 antagonists of the Cannabinoid-1 (CB1) receptor; treating obesity
12/08/2005US20050272762 Thienopyridines as IKK inhibitors
12/08/2005US20050272761 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/08/2005US20050272760 Use of pyridoindolone derivatives for the preparation of medicinal products
12/08/2005US20050272759 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; angiogenesis inhibitors; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration
12/08/2005US20050272758 Antineoplastic combinations of CCI-779 and rituximab
12/08/2005US20050272756 Pyridopyrrolizine and pyridoindolizine derivatives
12/08/2005US20050272755 Method for treating abnormal cell growth
12/08/2005US20050272754 Polymorphic forms of rifaximin, processes for their production and uses thereof
12/08/2005US20050272752 Complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
12/08/2005US20050272751 Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine
12/08/2005US20050272747 Preparation of triazoles by organometallic addition to ketones and intermediates therefor
12/08/2005US20050272746 Selecting antihistaminically deactivated isomer; making stereospecific use; malaria therapy
12/08/2005US20050272745 Novel piperidine and piperazine derivatives
12/08/2005US20050272744 N-((4-((( 1R)-3 -(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide; trigger apoptosis through the inhibition of the Bcl family of proteins
12/08/2005US20050272742 Process for making aripiprazole particles
12/08/2005US20050272741 Novel methods of treatment for Fontan patients with protein losing enteropathy
12/08/2005US20050272740 Benzimidazole derivatives
12/08/2005US20050272739 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
12/08/2005US20050272738 Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor
12/08/2005US20050272737 Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor
12/08/2005US20050272736 Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
12/08/2005US20050272734 Aids therapy
12/08/2005US20050272733 1-substituted pyridine-2-ones or 2-substituted pyridazin-3-ones; anticarcinogenic agents for breast and prostate cancer; contraceptives; endometriosis, benign prostatic hypertophy
12/08/2005US20050272732 5-ethyl-imidazo (5,1-F) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors
12/08/2005US20050272730 Thienopyridazines as IKK inhibitors
12/08/2005US20050272729 Cytotoxic agents comprising taxanes and their therapeutic use
12/08/2005US20050272728 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
12/08/2005US20050272727 As antitumor and anticancer agents
12/08/2005US20050272726 Novel medicaments for the treatment of respiratory diseases
12/08/2005US20050272725 Mixture of water, solvent, cosolvent and lipase used for hydrolyzing ester bond; specific, high yield and purity; performed at moderate temperatures and pH
12/08/2005US20050272724 Spin trapping pharmaceutical compositions and methods for use thereof
12/08/2005US20050272723 Methods and compositions for treating diseases and conditions associated with mitochondrial function
12/08/2005US20050272722 Methods for the treatment of synucleinopathies
12/08/2005US20050272721 Stable salts of olanzapine
12/08/2005US20050272720 Process for making olanzapine Form I
12/08/2005US20050272719 Method for inhibiting detrusor muscle overactivity
12/08/2005US20050272718 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
12/08/2005US20050272717 Treatment of aromatase inhibitor therapy-related osteoporosis
12/08/2005US20050272716 Use of parthenolide derivatives as antileukemic and cytotoxic agents
12/08/2005US20050272715 Optically active dihydropyridine derivative
12/08/2005US20050272714 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
12/08/2005US20050272713 Supramolecular complexes as photoactivated DNA cleavage agents
12/08/2005US20050272712 Compositions and methods for treatment of premenstrual dysphoric disorder
12/08/2005US20050272711 Substance for lowering high cholesterol level in serum and methods for preparing and using the same
12/08/2005US20050272710 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals
12/08/2005US20050272709 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death
12/08/2005US20050272708 phosphoinositol ether lipid analogues and bioisosteres thereof;serine/threonine kinase (protein kinase B (PKB)) inhibitor; antitumor and anticarcinogenic agent; decreasing phosphorylation, increasing apoptosis in a tumor cell, and inhibiting pleckstrin homology (PH) domain binding
12/08/2005US20050272707 Method for preventing or reducing secondary fractures after hip fracture
12/08/2005US20050272706 Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent
12/08/2005US20050272705 Method of adminstering bisphosphonates
12/08/2005US20050272704 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/08/2005US20050272703 Anti-tumor agents
12/08/2005US20050272702 Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls
12/08/2005US20050272701 Pharmaceutical composition
12/08/2005US20050272700 Topical treatment and prevention of human papilloma virus (HPV) infection
12/08/2005US20050272699 1- and 2-substituted with carbo- or heterocyclic groups, e.g., 3-[4-(5-Difluoromethoxy-3-trifluoromethyl-pyrazol-1-yl)-phenyl]-2-(2-fluoro-phenyl)-acrylonitrile; inhibit the production of IL-2.
12/08/2005US20050272698 Liquid stable composition of oxazaphosphorine with mesna
12/08/2005US20050272697 Composition and method for treating post-surgical pain
12/08/2005US20050272696 Treating a patient biopsy with different labeled, monodisperse glycosaminoglycans to determine the most effective angiogenesis inhibitor or anticarcinogenic agent; choosing and administering the identified agent
12/08/2005US20050272695 Fast dissolving dried hyaluronic acid product
12/08/2005US20050272694 Composition containing beta-glucan and constipation-relieving drug, immunopotentiatior, and skin moistening agent using the composition
12/08/2005US20050272693 Prophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
12/08/2005US20050272692 Sucrose ester compounds useful as fungicides
12/08/2005US20050272691 Treatment of dermatological conditions
12/08/2005US20050272690 Compositions and methods for sleep regulation
12/08/2005US20050272689 Methods, compositions, and kits for organ protection during systemic anticancer therapy
12/08/2005US20050272688 Combined treatment with gemcitabine and an epidermal growth factor receptor kinase inhibitor
12/08/2005US20050272687 Stable S-adenosyl-l-methionine
12/08/2005US20050272686 Nucleotide based medicament and method of use for treatment of conditions in humans
12/08/2005US20050272685 Intraductal treatment targeting methylated promoters in breast cancer
12/08/2005US20050272684 Breast cancer resistance protein (BCRP) and the DNA which encodes it
12/08/2005US20050272683 Antisense oligonucleotides against thymidylate synthase
12/08/2005US20050272681 Ribosome structure and protein synthesis inhibitors
12/08/2005US20050272676 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
12/08/2005US20050272675 Methods for isolating crystalline form I of 5-azacytidine
12/08/2005US20050272674 Selective hydrolysis of acarbose, acarbose derivatives with trifluoroacetic acid, removing the byproducts, i.e., monosaccharides, disaccharides, and trisaccharides; purifying valienamine in presence of ion-exchange resins
12/08/2005US20050272673 Administering purine nucleoside for treatment of arthritis inflammation
12/08/2005US20050272672 Ketolide anti-infective compounds
12/08/2005US20050272671 Compositions comprising hepoxilin analogs and their use in the treatment of cancer
12/08/2005US20050272669 treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
12/08/2005US20050272668 Anti-inflammatory compositions and methods
12/08/2005US20050272667 Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor
12/08/2005US20050272666 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
12/08/2005US20050272654 NF-kappaB activation inhibitors, and their pharmaceutical uses
12/08/2005US20050272649 Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
12/08/2005US20050272647 Arthrodial cartilage extracellular matrix degradation inhibitor
12/08/2005US20050272644 Method for increasing therapeutic gain in radiotherapy and chemotherapy
12/08/2005US20050272642 Protecting a muscarinic acetylcholine receptor in Alzheimer patients from oxidative stress, detoxification from toxic metal, by administering at least one pyrophosphates; prevent tissue damage, increasing the efficacy of a therapeutic agent
12/08/2005US20050272641 Therapeutic agents for diabetes
12/08/2005US20050272639 Crystalline polymorph of the pentahydrate form in synergistic combination with another active ingredient to enhance drug delivery; antidiabetic agents
12/08/2005US20050272638 Improved bioavailability; for oral and intracolonic administration
12/08/2005US20050272633 Derivatives of the nf-kappab inducing enzyme, their preparation and use
1 ... 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 ... 7860